These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 10878487)
1. Humoral and cellular autoimmunity in autoimmune bullous skin disorders. Hertl M Int Arch Allergy Immunol; 2000 Jun; 122(2):91-100. PubMed ID: 10878487 [TBL] [Abstract][Full Text] [Related]
2. Analysis of the T cells that are potentially involved in autoantibody production in pemphigus vulgaris. Hertl M; Riechers R J Dermatol; 1999 Nov; 26(11):748-52. PubMed ID: 10635617 [TBL] [Abstract][Full Text] [Related]
3. The desmosome and hemidesmosome in cutaneous autoimmunity. Lin MS; Mascaró JM; Liu Z; España A; Diaz LA Clin Exp Immunol; 1997 Jan; 107 Suppl 1():9-15. PubMed ID: 9020929 [TBL] [Abstract][Full Text] [Related]
4. Frequency analysis of autoreactive T-helper 1 and 2 cells in bullous pemphigoid and pemphigus vulgaris by enzyme-linked immunospot assay. Eming R; Büdinger L; Riechers R; Christensen O; Bohlen H; Kalish R; Hertl M Br J Dermatol; 2000 Dec; 143(6):1279-82. PubMed ID: 11122034 [TBL] [Abstract][Full Text] [Related]
5. Dichotomy of autoreactive Th1 and Th2 cell responses to desmoglein 3 in patients with pemphigus vulgaris (PV) and healthy carriers of PV-associated HLA class II alleles. Veldman C; Stauber A; Wassmuth R; Uter W; Schuler G; Hertl M J Immunol; 2003 Jan; 170(1):635-42. PubMed ID: 12496453 [TBL] [Abstract][Full Text] [Related]
6. Pathogenic IgG antibodies against desmoglein 3 in pemphigus vulgaris are regulated by HLA-DRB1*04:02-restricted T cells. Eming R; Hennerici T; Bäcklund J; Feliciani C; Visconti KC; Willenborg S; Wohde J; Holmdahl R; Sønderstrup G; Hertl M J Immunol; 2014 Nov; 193(9):4391-9. PubMed ID: 25252957 [TBL] [Abstract][Full Text] [Related]
7. T-cellular autoimmunity against desmogleins in pemphigus, an autoantibody-mediated bullous disorder of the skin. Hertl M; Veldman C Autoimmun Rev; 2003 Sep; 2(5):278-83. PubMed ID: 12965179 [TBL] [Abstract][Full Text] [Related]
8. Enzyme-linked immunosorbent assay in autoimmune blistering diseases: preliminary experience of the Dermatology Department of Cagliari. Atzori L; Deidda S; Aste N G Ital Dermatol Venereol; 2008 Feb; 143(1):1-8. PubMed ID: 18833046 [TBL] [Abstract][Full Text] [Related]
9. Induction of T regulatory cells by the superagonistic anti-CD28 antibody D665 leads to decreased pathogenic IgG autoantibodies against desmoglein 3 in a HLA-transgenic mouse model of pemphigus vulgaris. Schmidt T; Willenborg S; Hünig T; Deeg CA; Sonderstrup G; Hertl M; Eming R Exp Dermatol; 2016 Apr; 25(4):293-8. PubMed ID: 26661498 [TBL] [Abstract][Full Text] [Related]
10. [Autoimmune bullous skin diseases]. Joly P Rev Med Interne; 1999 Jan; 20(1):26-38. PubMed ID: 10220817 [TBL] [Abstract][Full Text] [Related]
11. Skin-infiltrating T cells display distinct inflammatory signatures in lichen planus, bullous pemphigoid and pemphigus vulgaris. Schinner J; Cunha T; Mayer JU; Hörster S; Kind P; Didona D; Keber C; Hertl M; Worzfeld T; Juratli HA Front Immunol; 2023; 14():1203776. PubMed ID: 37415985 [TBL] [Abstract][Full Text] [Related]
12. The role of T cells in pemphigus vulgaris and bullous pemphigoid. Fang H; Li Q; Wang G Autoimmun Rev; 2020 Nov; 19(11):102661. PubMed ID: 32942041 [TBL] [Abstract][Full Text] [Related]
13. T cell control in autoimmune bullous skin disorders. Hertl M; Eming R; Veldman C J Clin Invest; 2006 May; 116(5):1159-66. PubMed ID: 16670756 [TBL] [Abstract][Full Text] [Related]
14. Type 2 T-Cell Responses against Distinct Epitopes of the Desmoglein 3 Ectodomain in Pemphigus Vulgaris. Didona D; Scarsella L; Hudemann C; Volkmann K; Zimmer CL; Beckert B; Tikkanen R; Korff V; Kühn K; Wienzek-Lischka S; Bein G; Di Zenzo G; Böhme J; Cunha T; Solimani F; Pieper J; Juratli HA; Göbel M; Schmidt T; Borradori L; Yazdi AS; Sitaru C; Garn H; Eming R; Fleischer S; Hertl M J Invest Dermatol; 2024 Feb; 144(2):263-272.e8. PubMed ID: 37717934 [TBL] [Abstract][Full Text] [Related]
15. Identification and characterization of autoreactive T cell responses to bullous pemphigoid antigen 2 in patients and healthy controls. Büdinger L; Borradori L; Yee C; Eming R; Ferencik S; Grosse-Wilde H; Merk HF; Yancey K; Hertl M J Clin Invest; 1998 Dec; 102(12):2082-9. PubMed ID: 9854043 [TBL] [Abstract][Full Text] [Related]
16. Development and characterization of desmoglein-3 specific T cells from patients with pemphigus vulgaris. Lin MS; Swartz SJ; Lopez A; Ding X; Fernandez-Vina MA; Stastny P; Fairley JA; Diaz LA J Clin Invest; 1997 Jan; 99(1):31-40. PubMed ID: 9011573 [TBL] [Abstract][Full Text] [Related]
17. Recognition of desmoglein 3 by autoreactive T cells in pemphigus vulgaris patients and normals. Hertl M; Amagai M; Sundaram H; Stanley J; Ishii K; Katz SI J Invest Dermatol; 1998 Jan; 110(1):62-6. PubMed ID: 9424089 [TBL] [Abstract][Full Text] [Related]
18. Clinical activity of pemphigus vulgaris relates to IgE autoantibodies against desmoglein 3. Nagel A; Lang A; Engel D; Podstawa E; Hunzelmann N; de Pita O; Borradori L; Uter W; Hertl M Clin Immunol; 2010 Mar; 134(3):320-30. PubMed ID: 20015693 [TBL] [Abstract][Full Text] [Related]
19. Involvement of T(H)1/T(H)2 cytokines in the pathogenesis of autoimmune skin disease-Pemphigus vulgaris. Satyam A; Khandpur S; Sharma VK; Sharma A Immunol Invest; 2009; 38(6):498-509. PubMed ID: 19811408 [TBL] [Abstract][Full Text] [Related]
20. Heterogeneous MHC II restriction pattern of autoreactive desmoglein 3 specific T cell responses in pemphigus vulgaris patients and normals. Hertl M; Karr RW; Amagai M; Katz SI J Invest Dermatol; 1998 Apr; 110(4):388-92. PubMed ID: 9540980 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]